Clinical Trials

Phase 3 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03701282 2026-03-18

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT02160015 2026-03-17

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02947347 2026-03-17

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Phase 3 Completed

445 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT06136559 2026-03-16

BELLWAVE-011

Phase 3 Recruiting

1,200 enrolled

Phase 4 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07474961 2026-03-16

BLOOD-dose

400 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT05963074 2026-03-13

TAILOR

320 enrolled

Phase 3 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03462719 2026-03-12

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05254743 2026-03-12

BRUIN-CLL-314

Phase 3 Recruiting

662 enrolled

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase 1/2 Recruiting

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04802590 2026-03-04

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

194 enrolled

Lymphoma, Mantle-Cell

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT01880567 2026-02-19

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

113 enrolled

Lymphoma, Mantle-Cell

NCT02446236 2026-02-19

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT02756897 2026-02-19

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

234 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

30 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT07082868 2026-02-17

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Phase 1 Recruiting

26 enrolled

CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

NCT05998642 2026-02-12

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

30 enrolled

Lymphoma, Non-Hodgkin

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT02649387 2026-02-10

MERIT

Phase 2 Completed

35 enrolled 7 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03282396 2026-02-06

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

20 enrolled

Lymphoma, Mantle-Cell

NCT03513562 2026-02-06

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

28 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Phase 1/2 Recruiting

27 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Mantle-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

87 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03021460 2026-01-20

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

20 enrolled

Dermatologic

Melanoma

NCT03697512 2026-01-15

MALIBU

175 enrolled

Phase 1/2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone

NCT03960840 2026-01-09

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

217 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Phase 1 Recruiting

37 enrolled

CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02518555 2026-01-07

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

42 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02787369 2026-01-07

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

3 enrolled

Leukemia, Leukemia, B-Cell

NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

15 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03708003 2025-12-30

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Phase 2 Terminated

30 enrolled

Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06271616 2025-12-26

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant